Biologics/Update·FDA Vaccines, Blood & Biologics

Devices Guidances

LowPublished Apr 28, 2026· AI-analyzed May 4, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

The FDA updated its Center for Biologics Evaluation and Research (CBER) web resources to provide a consolidated listing of Medical Device Guidance documents.

Who it affects

Companies developing or manufacturing medical devices and combination products regulated by CBER, as well as regulatory affairs and quality assurance departments within these organizations.

Why it matters

The centralization of device-specific guidance within the biologics division suggests an effort to streamline access to relevant regulatory expectations. While the source does not detail specific content changes, this repository serves as the primary reference point for maintaining compliance with CBER-specific device standards, which may differ from CDRH requirements for certain specialized products.

Practical takeaway

Regulatory affairs teams should audit internal guidance libraries against the updated CBER list to ensure active submission strategies align with current Center expectations. Periodically check this consolidated landing page for newly finalized or drafted guidance documents that may impact device-biologic combination products.

FDA source material

This page lists Medical Device Guidance documents.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.